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The present study was designed to explore if retinalde-
hyde, a natural metabolite of vitamin A, has any bio-
logic activity and is tolerated by human skin. 
Biologic activity was shown by the induction of cel-
lular retinoic acid-binding protein type 2 (CRABP 2) 
mRNA and protein; the rank order for CRABP-2 in-
crease was retinoic acid> retinaldehyde > 9 cis reti-
noic acid> retinol> p carotene. 
In volunteers treated 1- 3 months with 0.5, 0.1, and 
0.05% retinaldehyde, there was a dose-dependent and 
significant increase in epidermal thickness, keratin 14 
immunoreactivity, and Ki67-positive cells. The area of 
distribution of involucrin, trans glutaminase, and fi-
laggrin immunoreactivity was also increased in a dose-
dependent manner, and keratin 4 immunoreactivity 
R etinOic acid (RA) is widely used for topical therapy of several skin diseases; it also improves chronic solar . damage [1]. Topical RA causes irritation of the skin, which precludes its use in some skin diseases that re-spond to systemic retinoids [2]. It is still not estab-
lished if all the therapeutic activities of topical RA are mediated by 
nuclear receptors, or if irritation is necessary for obtaining these 
effects. Irritation might be explained, in part, by an "overload" of 
the RA-dependent pathways with non-physiologic amounts of ex-
ogenous RA in the skin [3]. 
The use of immediate RA precursors, such as retinol, retinalde-
hyde, and P carotene may prevent this "overload." Human kerati-
nocytes transform retinol into retinaldehyde and then into RA by 
two enzymatic steps involving dehydrogenases. The first step is rate 
limiting and reversible; retinaldehyde can be converted enzymati-
cally into either RA or retinol by human keratinocytes, both in vivo 
[4,5] and in vitro [6]. The rate of conversion depends on the state of 
keratinocyte differentiation; differentiating keratinocytes are able 
to convert retinaldehyde into RA at a higher rate than are non-dif-
ferentiated keratinocytes [6] . Epidermal cells have a weak capacity 
to transform retinol into retinaldehyde [4,5] . P carotene is not con-
verted into retinoids by epidermal cells (Siegenthaler G, unpub-
lished observations) . 
We hypothesized that retinaldehyde may be a precursor for topi-
cal use because i) it bypasses the first rate-limiting step of retinol 
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was induced in the upper epidermis. In pilot clinical 
tolerance studies, 229 patients received topical retinal-
dehyde at different concentrations; the 1 % preparation 
was tolerated by up to 70% of the treated subjects; tol-
erance of the 0.5% preparation was slightly better, 
whereas both 0.1 and 0.05% preparations applied on 
facial skin were well tolerated and allowed prolonged 
use (up to 3 years) in patients with inflammatory der-
matoses. 
These findings indicate that topical retinaldehyde 
has biologic activity and is well tolerated on human • 
skin. Key words: retinoic acid / 9 cis retinoic acid/ cellular 
retinoid binding proteins / retinol / p carotene. ] Invest Derma-
toI103:770-774,1994 
oxidation into RA and ii) only epidermal cells at the pertinent stage 
of differentiation and capable of oxydizing retinaldehyde would 
generate active ligand(s) . This would result in more controlled de-
livery of ligand(s) and possibly weaker side effects compared to 
direct application of RA or synthetic analogs. I 
Because no published data are avai lable concerning the topical use 
of retinaldehyde in humans, we have performed pilot studies to 
explore its biologic effects and tolerability. 
MATERIAL AND METHODS 
Patients and Volunteers The protocols have been approved by the com-
mittee for ethics of our institution (Commission d'ethique du departement 
de medecine et dermatologie, University Hospital, Geneva). 
To study the induction of cellular retinoid-binding proteins, healthy vol-
unteers were treated for 4 d with 1, 0.1, and 0.05% retinaldehyde under 
occlusion as previously described [7,8]. Healthy volunteers were treated 
once daily for 1 to 3 months (see results) with 0.5, 0.1, or 0.05% retinal de-
hyde on one forearm and the vehicle on the other forearm. Biopsies were 
taken from both arms at the end of the period of treatment and processed for 
histology, immunohistochemistry, and electronmicroscopy. 
Subjects with various skin problems gave their written consent to receive 
one application per day of retinaldehyde. Duration of the application period 
and concentration of retinaldehyde (from 0.05 to 1 %) depended on the type 
of skin problem and are detailed in Results. Follow up was performed twice 
weekly in subjects treated with the highest concentrations (1 % and 0.5%) 
and once monthly in subjects receiving the 0.1 % and 0.05% preparations. 
Tolerance was evaluated subjectively by the subjects, and objectively by the 
authors concerning signs of irritation. Tolerance was graded on a 0 to 3 scale: 
0, no subjective or objective signs; 1, mild stinging and no objective signs; 2, 
stinging burning and visible erythema with subsequent fine scaling; 3, frank 
burning and erythema with edema. Photographs were taken at each visit. 
MATERIALS 
Reagents Retinol and retinoic acid were purchased from Sigma [11 ,12-
3H] all-trans retinoic acid (50.6 Ci/mmol) were obtained from Dupont 
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Figure 1. Topical retinaldehyde induces CRABP 2 mRNA. Northern 
blot analysis of CRABP 2 response to 4 d occlusive treatment with 0.05% 
retinaldehyde (R) versus vehicle (V). A, relative increase compared to vehi-
cle; densitometric analysis. B, results of two representative patients are 
shown. C, ethidium bromide staining of RNA samples after gel electropho-
resis. 
NEN, Germany. Analysis of the retinoids was performed under yellow 
light. Purity of labeled and unlabeled retinoids was checked by high-perfor-
mance liquid chromatography analysis and consistently exceeded 95%. All 
ethanol solutions of rctinoids contained butylated hydroxytoluenc. The 
other chemicals used were of best grade commercially available. 
Topical Relinaldehyde Preparations: Retinaldehyde (Eastman Kodak, Roch-
ester, NY) was prepared in lotion and cream vehicles at the concentrations of 
1,0.5,0.1, and 0.05% and did not contain detectable amounts of retinol and 
retinoic acid. 
Hybridizatioll probes: Full-length (740 bp) cellular retinoic acid-binding 
protein type 1 (CRABP 1) and (830 bp) mouse CRABP 2 cDNAs were 
kindly provided by Professor P. Chambon, CNRS LGME, Inserm U 184, 
Strasbourg, France, and RNA hybridizations were done as previously de-
scribed [9,10]. Human 28S ribosomal RNA cDNA was purchased from The 
American Type Culture Collection (Rockville, MD) and 32p labeled by 
random-priming using the Amersham Multiprime DNA labeling kit 
(Amersham, Buckinghamshire, England) according to the manufacturer's 
instructions. 
Analysis of CRABP-1 alld -2 Expression: CRABP 1 and 2 were analyzed at 
the mRNA and protein [11-13) levels after the ill lIivo short-term occlusive 
test previously described [7). Keratome biopsies were obtained after 4 d 
exposure to th~ followingcomI?ou.nds ~repared i~ the same cream vehicle: 
retinol, retinOlC aCId, 9 CIS retmolc aCId, or retmaldehyde (0.05%), or P 
carotene (0.5%). In each volunteer, one buttock was treated with the com-
pound, and the other received the vehicle. In another series of experiments, 
CRABP 2 protein induction was studied after application of 1 % or 0.1 % 
, retinaldehyde. 
Polyacrylamide Gel Electrophoresis and Autoradioblot/ing: The tissue samples 
were washed with phosphate-buffered saline (PBS) to remove traces of blood 
before being frozen and lyophilized. Protein extractions were performed as 
previously described (11). Binding proteins were analyzed after incubation 
of 100 ttl of supernatant (300 ttg of protein) with all traIlS [11, 12-3H) retinoic 
acid at 600 nM for 16 h at 4· C in the presence or absence of a 200-fold 
• excess of unlabeled ligand. The supernatants incubated with tritiated ligand 
were subjected to vertical-slab non-denaturing polyacrylamide gel electro-
phoresis with 7.5% acrylamide, as previously described [11 - 13). After e1ec-
Table I. Induction of CRABP-2 Protein Following 4 d 
of Occlusive Treatment with Retinaldehyde 
1 % retinaldehyde 
0.1 % retinaldehyde 
in Human Volunteers· 
Treated 
30.9 ± 8.3b 
24.1 ± 6.3' 
Vehicle 
7.1 ± 3.5 
3.1 ± 5 
• Values (pmol/mg protein) are mean of three polyacrylamide gel electrophoresis 
assay duplicate experiments ± SO. 
h P < 0.05, paired Wilcoxon's test. 
, p < 0.02, paired Wilcoxon's tcst. 
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Figure 2. Topical retinaldehyde induces CRABP 2 protein. CRABP 
2 protein following 4 d occlusive treatment; all compounds were applied at 
the concentration of 0.05% except p carotene (0.5%). Densitometric analy-
sis of polyacrylamide gel electrophoresis autoradioblotting; mean ± SD. 
trophoresis, the gel was either divided into lanes and cut into 2-mm bands, 
which were then assayed for the determination of the radioactivity profiles, 
or transferred to a nitro-cellulose sheet and analyzed by direct autoradiogra-
phy [13). The relative amounts of CRABP 1 and 2 were estimated by densi-
tometric evaluation of band intensity using a computing densitometer (Mo-
lecular Dynamics Ltd, Kemsing, UK). 
RNA Isolatiotl atld Atlalysis: Total RNA was isolated from snap-frozen 
keratome biopsies using the RNA extraction kit purchased from Pharmacia 
(Pharmacia LKB Biotechnology AG, Dubendorf, Switzerland) according to 
the manufacturer's instructions. Twenty micrograms of total RNA were 
hybridized in parallel to CRABP 1 .and CRABP 2 cRNAs as previously 
desc~lbed [10) .. After quantificatIOn uSlllg a phosphorimager (Molecular Dy-
naI1llCS, Kemslllg, UK), the membranes were stripped and rehybridized to 
human 28S nbosomal cRNAs for normalization according to standard pro-
cedure [14). 
Hist~logy Frozen and Bouin (or Duboscq Brasil)-fixed paraffin-embed-
~ed bIOpSIes were used for histology with the following staining: hematoxy-
1111 and eosm, Gordon and Sweets, periodic acid Schiff reaction, and Rinehart 
Abu'I Haj's method. Slides were analyzed using a light microscope by two 
blmded IIlvestlgators. Epidermal thickness measured on frozen sections in 
Table II. Epidermal Thickness (,um) and Epidermal 
Ki-67 - Positive Cells (per mm length of epidermis) 
Following Daily Open Use of Topical Retinaldehyde as 
Compared to Vehicle-Treated Side 
n 





0.05%/1 month 5 
Epidermal thickness 
K.i67 cells/mm 
0.05%/3 months 5 
Epidermal thickness 
K.i67 cells/mm 
• p < 0.01, paired Wilcoxon's test. 
h p < 0.02, paired Wilcoxon's test. 
Vehicle Retinaldehyde 
(mean ± SD) (mean ± SD) 
75 ± 22 138 ± 7' 
57 ± 16 162±59b 
58 ± 11 103 ± 22 
78 ± 13 83 ± 23' 
36 ± 11 66 ± 62 
65 ± 17 83 ± 27b 
44±29 59 ± 37b 
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Table III. Summary of Alteration in Expression of Differentiation Markers Mter Topical Application of Retinaldehyde 
































• Denotes immunoreactivity in stratum conlcum and granulosum. 
" Continuous stainin g. 
I Discontinuous staining. 
micrometers from the base of the stratum corneum to the basement mem-
brane was assessed in ten high-power fields, and the mean thickness was used 
as described [15] . 
Electron Microscopy Samples were fixed by 3% glutaraldehyde solu-
tion, dehydrated, and embedded in araldite resin. Thin sections were ob-
served on a CM10 Philips electron microscope. 
Immunohistochemistry Four micrometer frozen sections were incu-
bated directly with mouse monoclonal antibodies to cytokeratin peptide (K) 
14 (Sigma Chemical Company, St. Louis, MO), Kl0 (Serotec, Oxford, 
England), invol ucrin, filaggrin (Biomedical Technologies Inc., Stoughton, 
MA), or Ki67 proliferating cell antigen (Jackson Immunoresearch Labora-
tories Inc., West Grove, PAl· 
Other frozen sections fixed with methanol for 5 min at -20· C followed 
by acetone for 5 min at -20· C were incubated with mouse monoclonal 
antibodies to K4, K13, K19 (Bio-Science Products AG, Emmenbrucke, 
Switzerland), ~5-6 (Boehringer Mannheim, Mannheim, D), or human 
trans glutaminase (BCl clone, Biomedical Technologies Inc., Stoughton, 
MA). The horseradish peroxidase Vectastain ABC kit (Vector Laboratories 
Inc., Burlingame, CAl was used according to the manufacturer's instruc-
tions. 
Quantification of immunochemical staining reactions was performed as 
follows: for Ki67, the number of positive cells was counted per millimeter 
length of epidermis on three consecutive serial sections and the mean num-
ber was used; for the other markers, the thickness of the specific epidermal 
staining was measured in micrometers on ten high-power fields. 
Statistical Analysis All treatment versus vehicle individual values were 
assessed with the non-parametric paired Wilcoxon's test. 
RESULTS 
Topical Retinaldehyde Up-Regulates CRABP 2 CRABP 2 
mRNA was, as expected, barely detectable by Northern blot analy-
sis in vehicle-treated normal human skin but was induced following 
4 d occlusive treatment with 0.05% retinaldehyde (Fig 1). CRABP 
1 mRNA was not detectable in either vehicle or retinaldehyde-
treated skin samples. 
CRABP 2 protein was increased following 4 d occlusive treat-
ment with retinaldehyde (Table I and Fig 2), but there was no 
irritation at the site of application. Figure 2 compares the CRABP 2 
protein increase induced by 0.05% retinaldehyde, RA, 9 cis RA, or 
retinol at the same concentration in the same cream vehicle. The 
rank order for CRABP-2 increase was RA > retinaldehyde > 9 cis 
RA > retinol; interestingly, 0.5% fJ carotene (i.e ., a tenfold higher 
concentration) did not increase CRABP 2 levels. 
CRABP 1 protein was reduced by 60% in 0.05% retinaldehyde-
treated skin compared to vehicle alone; a reduction was also ob-
served with RA (-42%), retinol (-43%), and fJ carotene (-36%) 
but not 9 cis RA (not shown). 
Topical Retinaldehyde Increases Epidermal Thickness 
Skin samples obtained from volunteers treated daily on the forearm 
for 1 (0.5% and 0 .05%) or 3 months (0.05%) with retinaldehyde 
were compared to contralateral skin treated with vehicle alone. 
Retinaldehyde 0.05% 
1 Month (n = 5) 
, Focal staining . 
C Sec text. 





















Table II shows that retinaldehyde induced a dose-dependent sig-
nificant increase in epidermal thickness. No qualitative microscopic 
alterations were observed except for an increase in thickness of the 
granular layer in 0.5% retinaldehyde- treated samples; there was no 
deposition of mucin-like material. 
A detailed analysis was made by electron microscopy on one spec-
imen of skin treated for 1 month with 0.5, 0.1, or 0.05% retinal de-
hyde and for 3 months with 0.05% retinal de hyde. No significant 
ultrastructural changes were observed in the retinaldehyde-treated 
skin compared to vehicle; notably no deposition of mucin-like ma-
terial was found . 
Topical Retinaldehyde Increases Expression of Filaggrin, 
Transglutaminase and Involucrin and Induces Immunoreac-
tivity ofK4 The most important changes compared to the vehi-
cle-treated skin were observed in specimens from subjects treated 
with 0.5% retinaldehyde (Tables III and IV, Fig 3): K14 immu-
noreactivity was confined to the basal layer in all vehicle-treated 
samples and was induced in the supra-basal layers in all volunteers 
treated with 0.5% retinaldehyde; the number of Ki67-positive cells 
in the basal epidermal layers was increased threefold (Table II): K4 
immunoreactivity was not detectable in vehicle-treated samples but 
was present in the upper part of the epidermis in all volunteers 
treated with 0.5% retinaldehyde (Table III and Fig 3a); the area of 
distribution of transglutaminase, involucrin, and filaggrin immuno-
reactivities was increased in all 0.5% retinaldehyde - treated samples 
(Table III and Fig 3b, c, and d, respectively). In contrast, no 
changes were observed for K10, 5 and 6,13, and 19 immunoreactiv-
ities. 
The only consistent changes observed in specimens from subjects 
treated with 0.05% retinaldehyde were the slight and focal expres-
sion of K4 immunoreactivity in the upper epidermis (Table III), 
the slight but not significant increase in filaggrin involucrin and 
transglutarninase expression (Table IV), and a slight but significant 
increase in Ki67-positive cells (Table II) at 3 months. 
Table IV. Thickness of Immunoreactive epidermis for 
Markers of Differentiation (um)' 
n Involucrin Filaggrin Transglutaminase 
0.5% retinaldehyde 5 93 ± 13b 76 ± 5b 74± 7b 
1 month 
Vehicle 1 month 5 18 ± 1 24 ±2 12 ± 0.5 
0.05% retinal de hyde 5 27 ± 11 32 ± 13 19 ± 6 
1 month 
Vehicle 1 month 5 15 ± 1 23 ± 1 13 ±0.5 
0.05% retinaldehyde 5 13 ±2 38 ±4 11 ±2 
3 months 
Vehicle 3 months 5 12 ± 3 38 ±4 11 ± 2 
• The thickness of the specific epidermal staining was measured in ten high-power 
fields . 
I p < 0.01, paired Wilcoxon's test. 
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Figure 3. Topical retinaldehyde induces expression of filaggrin, t~ansglutaminase, involucrin, and keratin 4. Immunoreactivity of keratin 4 (a), 
transglutaminase (b), involucrin (c), and filaggrin (d) in human forearm skill treated for 1 month with 0.5% retinal de hyde (R) compared to contralateral side 
treated with vehicle (V). Bar, 75 j.tm. 
Topical Retinaldehyde Is Tolerated by Human Skin Two 
hundred twenty-nine f'atients received topical retinaldehyde at dif-
ferent concentrations (Table V). The 1 % preparation was tolerated 
by up to 69% of the treated subjects, mostly psoriatics treated on the 
trunk and limbs; grade 2 to 3 irritation leading to cessation of treat-
ment was observed in 31 %. Tolerance of the 0.5% preparation was 
slightly better, whereas both 0.1 and 0.05% preparations, used 
mostly on facial skin [16], were well tolerated (Table V). 
DISCUSSION 
To date we have found no report in the literature concerning the 
topical use of retinaldehyde on human skin. Our study was under-
taken to explore whether this natural metabolite of vitamin A has a 
biologic activity and is tolerated when applied on human skin. Our 
results show that topical retinaldehyde has biologic activity. This 
was demonstrated through two approaches: the induction of 
CRABP 2 and morphologic observations. 
Topical RA had been shown to increase CRABP 2 protein [7,12] 
and to induce CRABP 2 mRNA expression in human skin [8,17]; 
this latter effect has been proposed to be a good correlate of biologic 
activity [ 17]. We found that retinaldehyde likewise induces 
CRABP 2 mRNA expression and increases CRABP 2 protein. Fac-
tors that regulate the expression of CRABP 2 ill vivo are not fully 
understood. A "ligand-dependent" [18] pathway is most likely, be-
cause an increase in RA, both from endogenous enzymatic forma-
tion [4,10] and from exogenous delivery [7,8,12,17], is associated 
with an increase in keratinocyte CRABP 2 mRNA and protein. 
This pathway implies nuclear receptors such as retinoic acid recep-
tors (RARs) or retinoid X receptors (RXRs), because binding motifs 
have been identified in the mouse CRABP 2 gene that mediate RA 
differential transcription transactivation by RARs and RXRs [19]. 
Mouse CRABP 2 mRNA is also controlled post-transcriptionally by 
RA [20]. An apparently "ligand-independent" pathway [18] is also 
likely to exist, because CRABP 2 is induced in human epidermis by 
stimuli such as ultraviolet B irradiation, superficial epidermal 
wounding, and anthralin [7,12]. 
It is therefore not unlikely that CRABP 2 induction by topi-
cal RA, an irritant compound, may involve, at least in part, 
774 SAUltAT ET AL 
Table V. Tolerance of Topical Retinaldehyde 
on Human Skina 
Duration of 
Treatment 
Concentration Number of 
(months) Irritation' (0/0) 
(0/0) Patients Mean Rangeb 0 2 3 
1 26 1 0.3-1.4 54 15 19 12 
0.5 32 1.2 0.6-2 34 47 16 3 
0.1 52 4.5 2-13 75 19 6 0 
0.05 162 8.2 1-44 93 7 0 0 
It 1 % and 0.50/0 concentrations were used mainly on psoriatic lesions of trunk and 
limb, whereas 0.1 % and 0.05% were used mainly on facial skin (seborrheic dermatitis, 
n = 29; rosacea, n = 23; acne vulgaris, n = 25; atopic dermatitis, n = 6, melasma, 
n = 6, photoaging, n ± 41). The total number of subjects treated was 229; several 
parients received more than one dose. 
I Shortest and longest duration of treatment. 
, Irritation was quantified using a three-point scale (see text). 
pathways that are not directly linked to the binding to nuclear 
receptors. 
The molecular mechanism through which retinaldehyde in-
duced CRABP 2 is therefore not established. Our observations 
favor, however, a ligand-dependent pathway, because i) retinal de-
hyde did not induce irritation and ii) retinol also induced CRABP 2, 
whereas P carotene did not, even at a tenfold higher concentration. 
Indeed, although retinaldehyde can be formed either from retinol or 
P carotene in the intestine [21], human keratinocyte extracts trans-
form retinol but notp carotene (Siegenthaler G, unpublished obser-
vations); this is in accordance with our finding that retinol induced 
CRABP 2 slightly less than retinaldehyde. Because retinaldehyde 
binds poorly (500 times less than RA) to members of the retinoic 
acid receptor~ family [22,23], CRABP-2 induction by topical retin-
aldehyde most probably results from its transformation by epider-
mal enzymes into active ligand(s). This study has been designed to 
test the biologic activity of retinaldehyde, not to rank precisely this 
activity in comparison to the other vitamin A derivatives tested. 
Therefore, because the bioavailability of retinol, 9 cis RA, and RA in 
the vehicle used has not been evaluated, one cannot make any firm 
conclusion on the actual potency of retinaldehyde compared to any 
of these compounds. 
The biologic activity of topical retinaldehyde was also demon-
strated by morphologic observations. At the high concentration of 
0.5%, many changes, except the absence of mucin deposition, were 
similar to that induced by 0.1 and 0.05% topical RA or 13 cis RA 
[15,24,25]. The alterations induced by 0.05% retinaldehyde were 
milder but significant. Because this concentration induced CRABP 
2 about as well as 0.05% RA, there is a dissociation between mor-
phologic changes and CRABP 2 induction, the latter being a more 
sensitive indicator of biologic activity, as observed previously by 
others [15]. The correlation between the induction of morphologic 
changes and clinical irritation requires additional study [26]. 
Topical retinaldehyde was well tolerated and could be used at 
rather high concentrations, but tolerance was dependent upon con-
centration. The highest concentrations (1-0.1 %) were tolerated by 
an unexpectedly high percentage of patients, and we think an im-
provement in delivery may even increase the tolerance of high 
concentrations. The 0.05% concentration was well tolerated and 
allowed prolonged use on facial skin in patients with inflammatory 
dermatoses. This indicates that this natural metabolite of vitamin A 
may be used as a topical agent on human skin. Its usefulness in 
several conditions is currently under evaluation [16] . 
K. Tamm, D. Grand, P. Carraux, M. -J. Carlier Deldoll, alld M. Pis/ellr are 
acktlowledged for excel/elJl technical/Jefp and L. Frcl/ch for reading the lIIatJJucript. 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
REFERENCES 
I. Weiss JS, Ellis CN, Headington JT, Tincoff T, Hamilton TA, Voorhees JJ: 
Topical tretinoin improves photo aged skin. A double blind vehicle-controlled 
study.)AMA 259:527-532, 1988 
2. Orfanos CE, Schmidt HW, Mahrle G, Gartmann H, Lever WF: Retinoic acid in 
psoriasis: its value for topical therapy with and without corticosteroids. BrJ 
Dennato/88:167 -182, 1973 
3. Duell EA, Astrom A, Griffiths CEM, Chambon P, Voorhees JJ: Human skin 
levels of retinoic acid and cytochrome P 450 hydroxyretinoic acid after topical 
application of retinoic acid in vivo compared to concentrations required to 
stimulate retinoic acid receptor mediated transcription in vitro. ] Cli" I,IVes( 
90:1269-1274, 1992 
4. Siegenthaler G, Gumowski Sunek D, Saurat JH: Metabolism of natural retinoids 
in psoriatic epidermis.) I,lIIest DermatoI95:47S -48S. 1990 
5. Siegenthaler G, Saurat ]H: Natural retinoids: metabolism and transport in human 
epidermal cells. In: Saurat JH (cd .). Reti,lOids: 10 Years Oil. Karger, Basel, 1991 , I 
pp 56-68 
6. Siegenthaler G, Saurat JH, Ponec M: Retinol ~nd retinal metabolism. Relation-
ship to the state of differentiation of cultured human keratinocytes. Bioc!.etn) 
268:371-378,1990 
7. Hirschel Scholz S, Siegenthaler G, Saurat JH: Ligand specific and non specific in 
vivo modulation of human epidermal cellular retinoic acid binding protein 
(CRABP). EllrJ Clill Illvest 19:220-227, 1989 
8. Piletta P,Jaconi S, Siegenthaler G, Didierjean L, SauratJH: Topical glucocorti-
costeroids differently modulate the expression of CRABP I and II in human 
skin. Exp Dermatol 3:23 - 28, 1994 
9. Didierjean L. Durand B, Saurat JH : Cellular retinoic acid - binding protein type II 
mRNA is overexpressed in human psoriatic skin as shown by in situ hybridiza-
tion. Bioe!.e," Biop!.ys Res Comtlllltl 180:204-208, 1991 
10. Siegenthaler G, Tomatis I, Didierjean L, Jaconi S, Saurat JH: Overexpression of 
cellular retinoic acid-binding protein type II (CRABP II) and down-regulation 
of CRABP I in psoriatic skin. Dermatology 185:251 -256, 1992 
11. Siegenthaler G, SauratJH: A slab gel electrophoresis technique for the measure-
ment of plasma retinol-binding protein, cellular retinol-binding and retinoic 
acid-binding proteins in human skin. Ellr) Biod .. m 166:209-214, 1987 
12. Siegenthaler G, Tomatis I, Chatellard-Gruaz D,Jaconi S, Eriksson U , SauratJH: 
Expression of CRABP I and II in human epidermal cells. Alteration of relative 
protein amounts is linked to the state of differentiation. Biodrem) 287:383-
389,1992 
13. Siegenthaler G: Gel electrophoresis of cellular retinoic acid-binding protein, cel-
lular retinol-binding protein, and serum retinol-binding protein. Met!.ods EII-
zrmoI189:299-307.1990 
14. Davis LG, Dibner MD, Battey JF: DNA hybridization. In: Davis LG, Dibner 
MD, Battey JF (cds.). Basic Met!.ods ill Molewlar Biology. Elsevier. New York, 
1986, pp 84-87 
15. Griffiths CEM, Elder JT, Bernard BA, Rossio P, Cromie MA, Finkel LJ, Shroot B, 
Voorhees JJ: Comparison of CD271 (Adapalene) and all-trans rctinoie acid in 
human skin: dissociation of epidermal effects and CRABP II mRNA expres-
sion.) Invest Dermatoll01:325 -328. 1993 
16. Siegenthaler G, Gumowski D, Saurat]H: Topical retinal de hyde On human skin. 
Clinical and biological observations. In: Linea MA, Packer L (cds.) . Retilloids: 
Fro," Basic Scie"ee to Clillical Affiliatiolls. Birkhauser, Basel 
17. Elder JT, Cromie MA, Griffiths CEM, Chambon P, Voorhees JJ: Stimulus-selec-
tive induction of CRABP 11 mRNA: a marker for retinoic acid action in human 
skin.) Illvest Dermatoll00:356-359, 1993 
18. Piletta PA, Saurat JH: Cellular retinoic acid-binding proteins (CRABP). Exp 
Derm 2:191-195,1993 
19. Durand B, Saunders M, Leroy P, Leid M, Chambon P: All trans and 9 cisretinoic 
acid induction of CRABP 11 transcription is mediated by ItAR-RXR hetero-
dimers bound to DR1 and DRZ repeated motifs. Cell 71:73-85, 1992 
20. MacGregor TM, Copeland NG, Jenkins NA, Giguere V: The murine gene for 
cellular retinoic acid binding protein type 11.) Bioi C/lCm 267:7777 - 7783,1992 
21. Lakshm.1n MR, Mychkovsky I, Attlesey M: Enzymatic conversion of all trans P 
carotene to retinal by a cytosolic enzyme from rabbit and rat intestinal mucosa. 
Proc Natl Acad Sci USA 86:9124-9128, 1989 
22. Crettaz M, Baron A, Siegellthaler G, Hunziker W: Ligand specificities of recom-
binant retinoic acid receptors RARo: and ltARp. Bioe!.em) 272:391 - 397, 1990 
23. Repa JJ, Hanson KK, Clagett Dame M: All-trans-retinol is a ligand for the 
retinoic acid receptors. Proc Natl Acad Sci USA 90:7293 - 7297, 1993 
24. Rosenthal DS, Griffiths CEM, Yuspa SH, Roop DR, Voorhees JJ: Acute or 
chronic topical retinoic acid treatment of human skin in vivo alters the expres-
sion of epidermal transglutatninasc, loricrin, involucrin, fil aggrin, and keratins 
6 and 13 but not keratins I, 10. and 14.) [liVest Dermatol98:343 - 350, 1992 
25. Steijlen PM, Happle R, van Muijen GNP, van de Kerkhof PCM: Topical treat-
ment with 13~cjs-retinoic acid improves Daricc's disease and induces the ex-
pression of a unique keratin pattern. Dermarologica 182: 178 -183, 1991 
26. Redfern CPF: Molecular markers of retinoid activity in skill.) [liVest Dermatol 
101 :250-251. 1993 
